Top 6 Practice-Changing Highlights from ACR26 Save
The content at ACR Orlando was vast. I looked at several posters/listened to many talks and heard from colleagues. So if I missed some great abstracts that will be practice changing for you, I apologize in advance.
Here is my list TOP 6 practice changing themes:
6. H2H of Bimekizumab vs Risankizumab for PsA
Winner is….Bimekizumab (BE BOLD) 49.1% versus 38.0% ACR50
(not sure which to choose if skin is bad)
Abstract 2804
5. Gout +RCT
Urate lowering #URAT1i +RCT Pozdeutinurad – not sure of safety in CKD and not all pts had failed allopurinol or febuxostat
Don’t know where it will fit as
LB20
4. RCT in inflammatory myositis (dermatomyositis + immune mediated necrotizing myopathy)
FcRN Efgartigimod
Truly + on endpoints and subsets both favored active Rx, pts on background IS stable doses
CK improved and muscle power
Some hypogammaglobulinemia in this class of meds
LB24
3. 2+RCTs in SjD
Dazzled by Dazodalibep (CD40Li)
LB22
Or should I choose Ianalumab – LTE presented LB14
(one neg FcRn RCT w Efgartigimod – RCT stopped Oct 2026)
2. SLE +RCTs
Dapirolizumab pegol (CD40Li) -LLDAS -Phase 3 RCT already published
Abstract 2916
Obinutuzimab (CD20 deep depleter) for LN and nonrenal SLE – both RCTs published
Abstract 2217 Improvements of components of SLEDAI
Litifilimab in cutaneous features with cross over PBO to active and sustained benefit at 1 yr on active Rx – new MOA inhibits dendritic cells
Abstract 0872
Afimetoran + RCT with once daily oral TLR7/8 inhibitor
Many high bar outcomes
LB23
1.Big winner is a loser…(of BMI that is excessive)
Retatrutide Phase 3 results for retatrutide (sc weekly) Once-weekly retatrutide (doses including 4 mg, 9 mg, or 12 mg
Retatrutide is a drug with 3 components: GLP-1 (Glucagon-like peptide-1), GIP (Glucose-dependent insulinotropic polypeptide), and Glucagon
Presentations were from the TRIUMPH-4 and TRIUMPH-1-OA studies(80 weeks)
Retatrutide reduced knee pain on WOMAC Pain subscale (reductions of approximately –3.66 to –4.30 points across retatrutide doses vs. –2.24 with placebo, p < 0.001)
Change body weight ranged from ‑18.6% to -28.7%!
This will change my practice, when this is available. The BIG question that ‘weighs’ on me, is it all due to weight loss or is it combined with anti-inflammatory properties that improve OA symptoms. The other question is – are the weight loss hormonal drugs DMOADs (disease modifying).

If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.